AXSM — Axsome Therapeutics, Inc.

Axsome Therapeutics, Inc. Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenue: Q4 2025 revenue reached $196 million, a 65% increase year-over-year. Full-year revenue was $639 million, up 66%.
• Product Sales:
  • Auvelity: Q4 sales were $155.1 million, a 68% increase year-over-year, with full-year sales totaling $507.1 million (74% increase).
  • Sunosi: Q4 revenue was $36.7 million (40% increase), with full-year sales of $124.8 million (32% increase).
  • Cymbravo: Generated $4.1 million in Q4 and $6.6 million for the full year.
• Net Loss: Q4 net loss was $28.6 million ($0.56 per share), improved from a loss of $74.9 million ($1.54 per share) in Q4 2024. Full-year net loss was $183.2 million ($3.68 per share), down from $287.2 million ($5.99 per share) in 2024.
• Cash Position: Ended 2025 with $323 million in cash and equivalents, slightly up from $315 million in 2024.

2. Strategic Updates and Business Highlights

• Product Pipeline:
  • Auvelity's supplemental NDA for Alzheimer's agitation received priority review with a PDUFA date of April 30, 2026.
  • Initiating Phase III trials for AXS-05 in smoking cessation and AXS-12 in narcolepsy.
  • AXS-17 (formerly AZD7325) is being developed for epilepsy, with Phase II trial-enabling activities underway.
• Sales Force Expansion: Plans to double the sales force to 600 representatives to support growth in MDD and potential ADA indications.
• Commercial Strategy: Strong performance from Auvelity, Sunosi, and Cymbravo, with a focus on enhancing prescriber access and expanding market coverage.

3. Forward Guidance and Outlook

• Anticipates continued revenue growth driven by Auvelity and the upcoming launch of Cymbravo and potential approval for Alzheimer's agitation.
• Expectation of increased gross-to-net discounts for Auvelity and Sunosi due to typical Q1 dynamics, with Auvelity’s discounts projected to rise to the mid-50% range.
• Confident that the current cash balance will fund operations until reaching cash flow positivity.

4. Bad News, Challenges, or Points of Concern

• Increased Gross-to-Net Discounts: Expected rise in discounts could pressure margins.
• Competitive Landscape: Potential competition from other CNS drugs, particularly in the Alzheimer's market with products like Rexulti.
• Regulatory Risks: The need for successful outcomes from ongoing clinical trials and regulatory approvals, particularly for new indications.
• Market Access: While coverage for Auvelity is improving, the transition to Medicare Part D for ADA may present challenges in securing optimal reimbursement.

5. Notable Q&A Insights

• FDA Guidance on Trials: Discussion on the implications of the FDA's new one-trial policy for ongoing studies, particularly regarding ADHD and binge eating disorder.
• Market Dynamics: Insights on the differentiation of Auvelity in the Alzheimer's agitation market compared to existing treatments, emphasizing its safety profile and rapid onset of action.
• Sales Strategy: Clarification on how the expanded sales force will target both primary care and psychiatric prescribers to maximize market penetration.
• Cymbravo Coverage: Ongoing negotiations with payers to improve coverage, with expectations for increased access as contracts are finalized.

Overall, Axsome Therapeutics demonstrated strong financial growth in 2025, with strategic initiatives aimed at expanding its CNS product portfolio and enhancing market presence, while also navigating potential challenges in competition and regulatory landscapes.